Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonneveld

Showing results (11-20 of 1,272) with videos related to

Pageof 128
Sort By:
Blood|March 13, 2010
More force or more smart?Pieter Sonneveld
JAMA Oncology|July 17, 2015
Multiple Myeloma--Better Drugs Ask for More Stringent EvaluationsPieter Sonneveld
Pathologie-Biologie|April 8, 1999
Drug resistance in multiple myelomaP Sonneveld
Acta Haematologica|September 17, 2005
European myeloma network: the value of collaborative researchPieter Sonneveld
Seminars in Oncology|February 1, 1995
The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimensP Sonneveld
Blood Advances|January 4, 2018
Should minimal residual disease negativity <i>not</i> be the end point of myeloma therapy?Pieter Sonneveld
The New England Journal of Medicine|April 17, 2024
Four-Drug Therapy for Multiple Myeloma. ReplyPieter Sonneveld
The Lancet. Gastroenterology & Hepatology|November 13, 2019
Core inhibitor therapy for chronic hepatitis BMilan J Sonneveld
Haematologica|April 2, 2016
Treatment of relapsed and refractory multiple myelomaPieter Sonneveld, Annemiek Broijl
Haematologica|May 2, 2016
Innovations in treatment and response evaluation in multiple myelomaRuth Wester, Pieter Sonneveld
Pageof 128

Showing results (11-20 of 1,272) with videos related to

Sort By:
Pageof 128
Blood|March 13, 2010
More force or more smart?Pieter Sonneveld
JAMA Oncology|July 17, 2015
Multiple Myeloma--Better Drugs Ask for More Stringent EvaluationsPieter Sonneveld
Pathologie-Biologie|April 8, 1999
Drug resistance in multiple myelomaP Sonneveld
Acta Haematologica|September 17, 2005
European myeloma network: the value of collaborative researchPieter Sonneveld
Seminars in Oncology|February 1, 1995
The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimensP Sonneveld
Blood Advances|January 4, 2018
Should minimal residual disease negativity <i>not</i> be the end point of myeloma therapy?Pieter Sonneveld
The New England Journal of Medicine|April 17, 2024
Four-Drug Therapy for Multiple Myeloma. ReplyPieter Sonneveld
The Lancet. Gastroenterology & Hepatology|November 13, 2019
Core inhibitor therapy for chronic hepatitis BMilan J Sonneveld
Haematologica|April 2, 2016
Treatment of relapsed and refractory multiple myelomaPieter Sonneveld, Annemiek Broijl
Haematologica|May 2, 2016
Innovations in treatment and response evaluation in multiple myelomaRuth Wester, Pieter Sonneveld
Pageof 128